Akebia Ther (AKBA)vsZoetis Inc (ZTS)
AKBA
Akebia Ther
$0.91
-4.66%
HEALTHCARE · Cap: $351.42M
ZTS
Zoetis Inc
$74.83
+2.99%
HEALTHCARE · Cap: $31.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 4001% more annual revenue ($9.53B vs $232.40M). ZTS leads profitability with a 28.0% profit margin vs -8.8%. ZTS earns a higher WallStSmart Score of 66/100 (B-).
AKBA
Avoid23
out of 100
Grade: F
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AKBA.
Margin of Safety
+10.5%
Fair Value
$143.83
Current Price
$74.83
$69.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Trading at 9.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Trading at 9.5x book value
2.9% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
AKBA has a balanced fundamental profile.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Debt/Equity. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : AKBA
The primary concerns for AKBA are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.16 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
AKBA profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.75 — expect wider price swings.
ZTS is growing revenue faster at 2.9% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (66/100 vs 23/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?